Entecavir , 10mMinDMSO , 142217-69-4

Synonym(s):
2-Amino-1,9-dihydro-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one;2-Amino-9-[(1S,3R,4S)-4-hydroxy-3-hydroxymethyl-2-methylene-cyclopentyl]-3,9-dihydro-purin-6-one;BMS 200475;SQ 34,676

CAS NO.：142217-69-4

Empirical Formula: C12H15N5O3

Molecular Weight: 277.28

MDL number: MFCD00907887

EINECS: 604-279-5

PRODUCT Properties

• Melting point: 249-252°C
• Boiling point: 661.4±65.0 °C(Predicted)
• Density: 1.81±0.1 g/cm3(Predicted)
• storage temp.: -20°C
• solubility: DMSO (Slightly), Methanol (Sparingly)
• pka: 14.22±0.60(Predicted)
• form: powder
• color: white to beige
• optical activity: [α]/D +25 to +40°, c = 0.2 in H2O
• Stability: Hygroscopic

Description and Uses

Entecavir is a cyclopentyl guanosine analog launched for the once-daily oral treatment of chronic hepatitis B virus (HBV) infection, and it is the third nucleoside or nucleotide analog to be marketed for this indication. Lamivudine, a deoxythiacytosine analog, and adefovir dipivoxil, a nucleotide analog, have been marketed since 1998 and 2002, respectively. Entecavir and adefovir are specifically indicated for HBV, whereas lamivudine is indicated for both HBV and HIV infections.

Entecavir is a new generation of guanine nucleoside analogues oral medicine for treatment of hepatitis B virus infection in, mainly for the treatment of adult patients with viral replication activity and serum transaminase continued to increase, or liver tissue for pathological activity of chronic hepatitis B, is currently down virus the fastest and the most powerful, the mutation rate lowest nucleoside analogues.

Safety

• Symbol(GHS): GHS07
• Signal word: Warning
• Hazard statements: H302-H315-H320-H335
• Precautionary statements: P264-P270-P301+P312-P330
• Safety Statements: 24/25
• WGK Germany: 3
• HS Code: 29339900